Y Intercept Hong Kong Ltd Makes New Investment in Zoetis Inc. $ZTS

Y Intercept Hong Kong Ltd bought a new stake in shares of Zoetis Inc. (NYSE:ZTS) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 15,837 shares of the company’s stock, valued at approximately $1,872,000.

Several other large investors have also modified their holdings of ZTS. Vanguard Group Inc. boosted its stake in shares of Zoetis by 12.9% during the fourth quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock valued at $6,011,802,000 after purchasing an additional 5,474,210 shares in the last quarter. J. Stern & Co. LLP raised its stake in Zoetis by 12,431.2% in the fourth quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock worth $3,028,423,000 after buying an additional 23,877,416 shares in the last quarter. State Street Corp raised its stake in Zoetis by 0.8% in the fourth quarter. State Street Corp now owns 19,796,891 shares of the company’s stock worth $2,490,845,000 after buying an additional 149,382 shares in the last quarter. Geode Capital Management LLC lifted its holdings in Zoetis by 1.7% during the fourth quarter. Geode Capital Management LLC now owns 11,327,679 shares of the company’s stock worth $1,420,294,000 after buying an additional 189,235 shares during the period. Finally, Norges Bank bought a new stake in Zoetis during the 4th quarter valued at $734,425,000. Institutional investors own 92.80% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. JPMorgan Chase & Co. decreased their price objective on Zoetis from $190.00 to $130.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Citigroup lowered their price target on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a report on Monday, May 18th. Argus reiterated a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Stifel Nicolaus decreased their target price on shares of Zoetis from $95.00 to $85.00 and set a “hold” rating for the company in a research report on Friday, June 26th. Finally, Morgan Stanley restated an “overweight” rating and issued a $115.00 target price on shares of Zoetis in a research note on Friday, May 15th. Eight research analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $123.46.

Insiders Place Their Bets

In other Zoetis news, Director Michael B. Mccallister acquired 3,000 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were purchased at an average price of $77.76 per share, for a total transaction of $233,280.00. Following the completion of the purchase, the director directly owned 24,524 shares of the company’s stock, valued at $1,906,986.24. The trade was a 13.94% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Frank A. Damelio bought 6,650 shares of the firm’s stock in a transaction that occurred on Wednesday, May 13th. The shares were acquired at an average price of $75.39 per share, with a total value of $501,343.50. Following the completion of the transaction, the director directly owned 21,458 shares of the company’s stock, valued at $1,617,718.62. This trade represents a 44.91% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last ninety days, insiders acquired 11,650 shares of company stock valued at $886,384. 0.22% of the stock is owned by insiders.

Zoetis Stock Down 0.1%

Zoetis stock opened at $75.06 on Friday. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. The business’s 50-day simple moving average is $80.73 and its two-hundred day simple moving average is $107.98. The company has a market cap of $31.47 billion, a PE ratio of 12.45, a PEG ratio of 1.17 and a beta of 0.75. Zoetis Inc. has a fifty-two week low of $71.47 and a fifty-two week high of $161.77.

Zoetis (NYSE:ZTS) last announced its quarterly earnings data on Thursday, May 7th. The company reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.60 by ($0.07). Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The firm had revenue of $2.26 billion during the quarter, compared to analysts’ expectations of $2.30 billion. During the same quarter in the previous year, the business earned $1.48 earnings per share. The company’s revenue for the quarter was up 2.9% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities analysts anticipate that Zoetis Inc. will post 6.88 EPS for the current year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 1st. Shareholders of record on Monday, July 20th will be given a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, July 20th. This represents a $2.12 dividend on an annualized basis and a yield of 2.8%. Zoetis’s dividend payout ratio (DPR) is currently 35.16%.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.